Complete Filing Data
Vicapsys Life Sciences, Inc. reported Stockholders Equity of -$121.7 thousand for FY2021.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Vicapsys Life Sciences, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Net Income * | -$1.2M | -$984.8K | -$236.9K | -$765.8K | -$1.4M |
| Operating Expenses | $1.0M | $984.8K | $336.9K | $765.8K | $1.0M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$1.2M | -$984.8K | -$236.9K | -$765.8K | -$1.0M |
| General And Administrative Expense | $96.4K | $60.2K | $35.8K | $47.0K | $54.1K |
| Research And Development Expense | $15.3K | $13.1K | $17.7K | $102.2K | $99.0K |
| Operating Income Loss | -$1.0M | -$984.8K | -$336.9K | -$765.8K | |
| Net Income Loss Available To Common Stockholders Basic | -$1.2M | -$988.3K | -$236.9K | -$765.8K | -$1.6M |
| Nonoperating Income Expense | -$135.1K | $100.0K | |||
| Income Loss From Continuing Operations Per Basic And Diluted Share | -$0.10 | -$0.10 | |||
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -$765.8K | -$1.0M | |||
| Interest Expense Nonoperating | $20.0K | ||||
| Other Nonoperating Income | $100.0K | ||||
| Income Taxes Paid Net | $545.00 | ||||
| Income Loss From Discontinued Operations Net Of Tax | -$375.8K | ||||
| Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share | -$0.03 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$235.5K | -$190.1K | -$327.1K | -$240.3K | -$135.7K | -$211.3K | -$145.1K | -$180.1K | -$167.0K | -$111.2K | -$72.1K | $50.2K | -$89.2K | -$231.6K | -$364.5K | -$469.3K | -$248.1K | -$442.7K |
| Operating Expenses | $198.9K | $181.8K | $204.3K | $175.4K | $135.7K | $211.3K | $145.1K | $180.1K | $167.0K | $111.2K | $72.1K | $49.8K | $89.2K | $231.6K | $364.5K | $469.3K | $151.3K | $163.6K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$235.5K | -$190.1K | -$327.1K | -$240.3K | -$135.7K | -$211.3K | -$145.1K | -$180.1K | -$167.0K | -$111.2K | -$72.1K | $50.2K | -$89.2K | -$231.6K | -$364.5K | -$469.3K | -$151.3K | -$163.6K |
| General And Administrative Expense | $4.1K | $2.8K | $34.9K | $26.9K | $15.3K | $3.8K | $12.3K | $16.2K | $12.8K | $8.6K | $9.2K | $8.6K | $13.5K | $8.9K | $14.1K | $18.1K | $8.5K | $8.7K |
| Research And Development Expense | $3.7K | $10.0K | $344.00 | $3.3K | $2.0K | $10.0K | $3.1K | $10.0K | $4.9K | $2.3K | $94.0K | $99.0K | ||||||
| Operating Income Loss | -$198.9K | -$181.8K | -$204.3K | -$175.4K | -$135.7K | -$211.3K | -$145.1K | -$180.1K | -$167.0K | -$111.2K | -$72.1K | -$49.8K | -$89.2K | -$231.6K | -$364.5K | |||
| Net Income Loss Available To Common Stockholders Basic | -$235.5K | -$190.1K | -$240.3K | -$135.7K | -$148.6K | -$111.2K | -$89.2K | -$364.5K | -$469.3K | -$603.1K | ||||||||
| Nonoperating Income Expense | -$36.6K | -$8.3K | $122.8K | -$64.9K | $100.0K | |||||||||||||
| Income Loss From Continuing Operations Per Basic And Diluted Share | -$0.01 | -$0.01 | -$0.02 | -$0.04 | -$0.02 | -$0.02 | ||||||||||||
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -$89.2K | -$231.6K | -$364.5K | -$469.3K | -$151.3K | -$163.6K | ||||||||||||
| Interest Expense Nonoperating | $36.6K | $8.3K | -$36.5K | $10.0K | ||||||||||||||
| Other Nonoperating Income | $100.0K | |||||||||||||||||
| Income Taxes Paid Net | ||||||||||||||||||
| Income Loss From Discontinued Operations Net Of Tax | -$96.7K | -$279.1K | ||||||||||||||||
| Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share | -$0.01 | -$0.03 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Stockholders Equity | -$121.7K | -$449.1K | $302.0K | -$253.7K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $217.3K | $1.3K | $264.2K | $86.3K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$4.7K | -$203.2K | $216.0K | -$262.9K | $177.8K | |
| Retained Earnings Accumulated Deficit | -$15.1M | -$14.1M | -$13.9M | -$13.1M | ||
| Liabilities Current | $1.0M | $716.0K | $853.2K | $396.5K | ||
| Common Stock Value | $31.2K | $19.7K | $17.5K | $17.5K | ||
| Liabilities And Stockholders Equity | $72.0K | $594.3K | $404.1K | $698.4K | ||
| Assets Current | $72.0K | $222.8K | $1.3K | $264.2K | ||
| Assets | $72.0K | $594.3K | $404.1K | $698.4K | ||
| Cash And Cash Equivalents At Carrying Value | $14.1K | $217.3K | $1.3K | $264.2K | ||
| Accounts Payable Current | $537.4K | $272.3K | $487.8K | $501.7K | $396.5K | |
| Common Stock To Be Issued | $727.00 | $12.1K | $651.00 | $651.00 | ||
| Accrued Salaries Current | $115.3K | $115.3K | $115.3K | $115.3K | ||
| Finite Lived Intangible Assets Accumulated Amortization | $0.00 | $121.0K | $89.7K | $58.2K | ||
| Intangible Assets Net Excluding Goodwill | $371.5K | $402.8K | $434.3K | |||
| Accounts Payable Related Parties Current | $272.3K | $112.9K | $236.2K | |||
| Accounts Payable Trade Current | $961.7K | $635.2K | ||||
| Deferred Offering Costs | $50.4K | |||||
| Convertible Notes Payable Current | ||||||
| Preferred Stock Dividends And Other Adjustments | $3.5K | |||||
| Additional Paid In Capital Common Stock |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$2.6M | -$2.4M | -$2.3M | -$1.9M | -$1.3M | -$1.1M | -$1.1M | -$950.8K | -$520.3K | -$466.6K | -$287.6K | -$193.9K | -$258.8K | -$397.8K | -$369.6K | -$294.1K | -$62.5K | $546.2K | $480.8K | -$696.3K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $89.6K | $9.4K | $53.5K | $231.3K | $4.1K | $14.1K | $26.2K | $17.3K | $101.3K | $165.5K | $170.6K | $30.5K | $1.7K | $5.0K | $30.9K | $510.6K | $430.8K | $3.1K | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$9.4K | -$10.0K | -$116.0K | $29.2K | -$233.2K | -$83.2K | |||||||||||||||
| Retained Earnings Accumulated Deficit | -$17.1M | -$16.8M | -$16.6M | -$16.3M | -$15.7M | -$15.5M | -$15.3M | -$14.6M | -$14.5M | -$14.3M | -$14.0M | -$13.9M | -$13.8M | -$13.8M | -$13.7M | -$13.5M | |||||
| Liabilities Current | $2.7M | $2.4M | $2.3M | $2.0M | $1.5M | $1.5M | $1.2M | $904.1K | $848.8K | $765.8K | $746.0K | $821.2K | $826.2K | $783.9K | $710.7K | $518.1K | |||||
| Common Stock Value | $32.4K | $32.1K | $32.1K | $32.1K | $32.1K | $31.2K | $31.2K | $31.2K | $31.2K | $31.2K | $17.5K | $17.5K | $17.5K | $17.5K | $17.5K | $17.5K | |||||
| Liabilities And Stockholders Equity | $89.6K | $39.7K | $208.5K | $378.1K | $63.3K | $383.8K | $382.2K | $478.2K | $552.2K | $562.4K | $428.4K | $414.3K | $427.4K | $461.0K | |||||||
| Assets Current | $89.6K | $39.7K | $208.5K | $378.1K | $63.3K | $35.7K | $26.3K | $114.5K | $165.5K | $175.2K | $33.4K | $3.6K | $8.9K | $30.9K | |||||||
| Assets | $89.6K | $39.7K | $208.5K | $378.1K | $63.3K | $383.8K | $382.2K | $478.2K | $552.2K | $562.4K | $428.4K | $414.3K | $427.4K | $461.0K | |||||||
| Cash And Cash Equivalents At Carrying Value | $89.6K | $9.4K | $53.5K | $231.3K | $4.1K | $101.3K | $165.5K | $170.6K | $30.5K | $1.7K | $5.0K | $30.9K | |||||||||
| Accounts Payable Current | $446.6K | $427.4K | $371.1K | $571.9K | $566.5K | $514.0K | $496.6K | $467.5K | $472.4K | $478.1K | $477.8K | $501.7K | |||||||||
| Common Stock To Be Issued | $1.5K | $727.00 | $727.00 | $627.00 | $627.00 | $12.6K | $11.9K | $11.1K | $651.00 | $651.00 | $651.00 | ||||||||||
| Accrued Salaries Current | $115.3K | $115.3K | $115.3K | $115.3K | $115.3K | $115.3K | $115.3K | $115.3K | $115.3K | $115.3K | $79.9K | $16.4K | |||||||||
| Finite Lived Intangible Assets Accumulated Amortization | $144.5K | $136.6K | $128.8K | $113.1K | $105.3K | $97.5K | $81.8K | $74.0K | $66.1K | ||||||||||||
| Intangible Assets Net Excluding Goodwill | $348.1K | $355.9K | $363.7K | $379.4K | $387.2K | $395.0K | $410.7K | $418.5K | $426.4K | ||||||||||||
| Accounts Payable Related Parties Current | $216.9K | $167.0K | $136.5K | $134.2K | $238.4K | $238.5K | $190.5K | $153.0K | |||||||||||||
| Accounts Payable Trade Current | $673.2K | $665.9K | $718.2K | ||||||||||||||||||
| Deferred Offering Costs | $102.7K | $69.1K | $50.4K | ||||||||||||||||||
| Convertible Notes Payable Current | $511.4K | $449.3K | $449.3K | $335.2K | $270.5K | $208.9K | |||||||||||||||
| Preferred Stock Dividends And Other Adjustments | $3.5K | ||||||||||||||||||||
| Additional Paid In Capital Common Stock | $14.1M | $14.0M | $14.0M | $14.0M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Financing Cash Flow * | $412.8K | $35.0K | $560.0K | $1.1M | |
| Operating Cash Flow * | -$417.5K | -$238.2K | -$444.0K | -$262.9K | -$970.3K |
| Share Based Compensation | $20.7K | $105.7K | $4.3K | $14.8K | $118.6K |
| Increase Decrease In Prepaid Expense | -$37.2K | $2.0K | $5.5K | ||
| Increase Decrease In Accounts Payable Trade | $326.5K | $112.0K | -$13.9K | ||
| Increase Decrease In Accounts Payable Related Parties | $265.1K | $159.5K | -$123.3K | ||
| Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net | $4.3K | $14.8K | $118.6K | ||
| Increase Decrease In Accounts Payable | -$13.9K | $105.3K | $46.5K | ||
| Proceeds From Issuance Of Common Stock | $100.0K | $560.0K | |||
| Increase Decrease In Accounts Payable Related Party | -$123.3K | $236.2K | |||
| Proceeds From Sale Of Equity Method Investments | $100.0K | ||||
| Net Cash Provided By Used In Investing Activities | $100.0K | ||||
| Proceeds From Warrant Exercises | $50.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2024 | Q1 2023 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Financing Cash Flow * | $104.5K | ||||||||||
| Operating Cash Flow * | -$9.4K | -$10.0K | -$116.0K | -$70.8K | -$233.2K | -$187.7K | |||||
| Share Based Compensation | $20.7K | $1.1K | $1.1K | $5.4K | |||||||
| Increase Decrease In Prepaid Expense | -$30.2K | $1.2K | $7.7K | $2.9K | $3.7K | ||||||
| Increase Decrease In Accounts Payable Trade | $85.9K | $83.0K | $26.2K | ||||||||
| Increase Decrease In Accounts Payable Related Parties | $93.5K | $98.8K | $23.6K | ||||||||
| Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net | $1.1K | $1.1K | $1.1K | $13.7K | $5.4K | $5.4K | $113.2K | ||||
| Increase Decrease In Accounts Payable | $26.2K | -$29.3K | $105.2K | $13.4K | |||||||
| Proceeds From Issuance Of Common Stock | $385.0K | $210.0K | |||||||||
| Increase Decrease In Accounts Payable Related Party | $23.6K | $2.3K | |||||||||
| Proceeds From Sale Of Equity Method Investments | $100.0K | $100.0K | |||||||||
| Net Cash Provided By Used In Investing Activities | $100.0K | ||||||||||
| Proceeds From Warrant Exercises |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.03 | -$0.03 | -$0.01 | -$0.04 | -$0.13 | |
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Preferred Stock Shares Authorized | 7.4M | 20.0M | 20.0M | 20.0M | 20.0M | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Weighted Average Number Of Shares Outstanding Basic | 34.5M | 30.6M | 17.7M | |||
| Earnings Per Share Basic | $-0.03 | $-0.03 | $-0.01 | |||
| Common Stock Shares Outstanding | 31.2M | 19.7M | 17.5M | 17.5M | ||
| Common Stock Shares Issued | 31.2M | 19.7M | 17.5M | 17.5M | ||
| Common Stock To Be Issued Shares Outstanding | 0.00 | 727.3K | 11.1M | 651.3K | 651.3K | |
| Common Stock To Be Issued Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Weighted Average Number Of Diluted Shares Outstanding | 34.5M | 30.6M | ||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 17.7M | 17.5M | 11.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.01 | -$0.01 | -$0.01 | -$0.01 | $0.00 | -$0.01 | $0.00 | -$0.01 | -$0.01 | -$0.01 | $0.00 | $0.00 | -$0.01 | -$0.01 | -$0.02 | -$0.04 | -$0.03 | -$0.05 | |
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Authorized | 7.4M | 7.4M | 7.4M | 7.4M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | ||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| Weighted Average Number Of Shares Outstanding Basic | 34.3M | 34.2M | 32.1M | 34.4M | 35.3M | 34.6M | 31.2M | 31.2M | 28.7M | 17.5M | 17.5M | 17.5M | 17.5M | ||||||
| Earnings Per Share Basic | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $0.00 | $-0.01 | $0.00 | $-0.01 | $-0.01 | $-0.01 | $0.00 | $0.00 | $-0.02 | ||||||
| Common Stock Shares Outstanding | 32.4M | 32.1M | 32.1M | 32.1M | 32.1M | 31.2M | 31.2M | 31.2M | 31.2M | 31.2M | 17.5M | 17.5M | 17.5M | 17.5M | 17.5M | 17.5M | |||
| Common Stock Shares Issued | 32.4M | 32.1M | 32.1M | 32.1M | 32.1M | 31.2M | 31.2M | 31.2M | 31.2M | 31.2M | 17.5M | 17.5M | 17.5M | 17.5M | 17.5M | 17.5M | |||
| Common Stock To Be Issued Shares Outstanding | 0.00 | 1.5M | 727.3K | 726.3K | 627.3K | 627.3K | 12.6M | 11.9M | 11.1M | 651.3K | 651.3K | 651.3K | 4.5M | 4.5M | 4.5M | ||||
| Common Stock To Be Issued Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Weighted Average Number Of Diluted Shares Outstanding | 34.3M | 34.2M | 32.1M | 34.4M | 35.3M | 34.6M | 31.2M | 31.2M | 28.7M | 17.5M | 32.3M | 17.5M | |||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 17.5M | 17.5M | 17.5M | 17.5M | 17.5M | 12.0M | 10.1M | 9.7M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Professional Fees | $672.7K | $448.8K | $191.9K | $330.4K | $474.4K |
| Personnel Costs | $262.6K | $122.5K | $91.5K | $286.3K | $406.4K |
| Additional Paid In Capital | $14.1M | $14.0M | $13.4M | $13.4M | |
| Adjustment For Amortization | $31.3K | $31.3K | $31.4K | $31.3K | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $20.7K | $105.7K | $4.3K | ||
| Prepaid Expense Current | $7.5K | $5.5K | |||
| Stock Issued During Period Value New Issues | $50.0K | $560.0K | $971.5K | ||
| Interest Paid Net | $20.0K | ||||
| Stock Issued During Period Shares New Issues | 100.0K | ||||
| Short Term Borrowings | |||||
| Gain Loss On Sale Of Investment | $100.0K | ||||
| Stock Issued During Period Value Other | $50.0K | ||||
| Financing Costs | $115.2K | ||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $83.5K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Professional Fees | $128.5K | $106.5K | $106.5K | $76.1K | $51.5K | $133.5K | $99.3K | $133.0K | $113.9K | $79.5K | $35.3K | $16.1K | $15.9K | $129.1K | $157.2K | $218.6K | $106.9K | $17.5K | |
| Personnel Costs | $62.5K | $62.5K | $62.5K | $69.2K | $66.9K | $64.0K | $30.5K | $30.9K | $30.4K | $23.1K | $22.7K | $22.8K | $59.8K | $93.7K | $99.1K | $133.7K | $35.9K | $137.4K | |
| Additional Paid In Capital | $14.4M | $14.3M | $14.3M | $14.3M | $14.3M | $14.3M | $14.2M | $13.8M | $13.6M | $13.4M | $13.4M | $13.4M | $13.4M | ||||||
| Adjustment For Amortization | $27.8K | $7.8K | $7.8K | $7.9K | $7.8K | ||||||||||||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $20.7K | $41.4K | $1.1K | $1.1K | $1.1K | $1.1K | $1.1K | ||||||||||||
| Prepaid Expense Current | $30.2K | $52.3K | $77.8K | $8.7K | $9.5K | $9.0K | $13.2K | $4.6K | $2.9K | $1.9K | $3.9K | ||||||||
| Stock Issued During Period Value New Issues | $100.0K | $175.0K | $210.0K | $421.5K | $550.0K | ||||||||||||||
| Interest Paid Net | $212.00 | ||||||||||||||||||
| Stock Issued During Period Shares New Issues | 1.5M | 840.0K | |||||||||||||||||
| Short Term Borrowings | $12.5K | $12.5K | $18.7K | $36.8K | $54.2K | ||||||||||||||
| Gain Loss On Sale Of Investment | $100.0K | ||||||||||||||||||
| Stock Issued During Period Value Other | $50.0K | ||||||||||||||||||
| Financing Costs | $55.0K | ||||||||||||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $35.6K | $83.5K |
Most recent annual filing with the SEC: October 21, 2024
Data sourced from SEC EDGAR public filings as of August 7, 2026.